Review

Islet and Stem Cell Encapsulation for Clinical Transplantation

Rahul Krishnan¹, Michael Alexander¹, Lourdes Robles¹, Clarence E. Foster 3rd^1,2, Jonathan R.T. Lakey^1,3

Manuscript submitted June 19, 2013; resubmitted August 1, 2013; accepted August 9, 2013.

Keywords: type 1 diabetes, stem cell, encapsulation, tissue engineering, insulin-producing cell, transplantation

Abstract

Over the last decade, improvements in islet isolation techniques have made islet transplantation an option for a certain subset of patients with long-standing diabetes. Although islet transplants have shown improved graft function, adequate function beyond the second year has not yet been demonstrated, and patients still require immunosuppression to prevent rejection. Since allogeneic islet transplants have experienced some success, the next step is to improve graft function while eliminating the need for systemic immunosuppressive therapy. Biomaterial encapsulation offers a strategy to avoid the need for toxic immunosuppression while increasing the chances of graft function and survival. Encapsulation entails coating cells or tissue in a semipermeable biocompatible material that allows for the passage of nutrients, oxygen, and hormones while blocking immune cells and regulatory substances from recognizing and destroying the cell, thus avoiding the need for systemic immunosuppressive therapy. Despite advances in encapsulation technology, these developments have not yet been meaningfully translated into clinical islet transplantation, for which several factors are to blame, including graft hypoxia, host inflammatory response, fibrosis, improper choice of biomaterial type, lack of standard guidelines, and post-transplantation device failure. Several new approaches, such as the use of porcine islets, stem cells, development of prevascularized implants, islet nanocoating, and multilayer encapsulation, continue to generate intense scientific interest in this rapidly expanding field. This review provides a comprehensive update on islet and stem cell encapsulation as a treatment modality in type 1 diabetes, including a historical outlook as well as current and future research avenues.

Fulltext: HTML , PDF (254KB)

This article has been cited by other articles:

	Islet Microencapsulation: Strategies and Clinical Status in Diabetes Omami M, McGarrigle JJ, Reedy M, Isa D, Ghani S, Marchese E, Bochenek MA, Longi M, Xing Y, Joshi I, Wang Y, Oberholzer J Curr Diab Rep 2017. 17(7):47
	Microencapsulation in Clinical Islet Xenotransplantation Shimoda M, Matsumoto S Methods Mol Biol 2017. 1479:335-345
	Engineering Cell Surfaces with Polyelectrolyte Materials for Translational Applications Zhang P, Bookstaver ML, Jewell CM Polymers 2017. 9(2):40
	A Synthetic Mammalian Therapeutic Gene Circuit for Sensing and Suppressing Inflammation Smole A, Lainscek D, Bezeljak U, Horvat S, Jerala R Mol Ther 2017. 25(1):102-119
	Does exercise pose a challenge to glucoregulation after clinical islet transplantation? Funk DR, Boule NG, Senior PA, Yardley JE Appl Physiol Nutr Metab 2017. 42(1):1-7
	Induction of Nestin Early Expression as a Hallmark for Mesenchymal Stem Cells Expression of PDX-1 as a Pre-disposing Factor for Their Conversion into Insulin Producing Cells Martinez-Gamboa M, Cruz-Vega DE, Moreno-Cuevas J, Gonzalez-Garza MT Int J Stem Cells 2017. 10(1):76-82
	Smart biomaterials for cell encapsulation Zhu H, Cao Z RSC Smart Mat Tiss Engin 2017. 144-168
	TGF-beta affinity-bound to a macroporous alginate scaffold generates local and peripheral immunotolerant responses and improves allocell transplantation Orr S, Strominger I, Eremenko E, Vinogradov E, Ruvinov E, Monsonego A, Cohen S Acta Biomater 2016. 45:196-209
	CD133+ cells: How could they have an IMPACT? Menasche P J Thorac Cardiovasc Surg 2016. 152(6):1589-1591
	Beta Cell Formation in vivo Through Cellular Networking, Integration and Processing (CNIP) in Wild Type Adult Mice Doiron B, Hu W, DeFronzo RA Curr Pharm Biotechnol 2016. 17(4):376-88
	Progress and challenges for treating type 1 diabetes Garyu JW, Meffre E, Cotsapas C, Herold KC J Autoimmun 2016. 71:1-9
	Progress and challenges of the bioartificial pancreas Hwang PT, Shah DK, Garcia JA, Bae CY, Lim DJ, Huiszoon RC, Alexander GC, Jun HW Nano Converg 2016. 3(1):28
	Application of encapsulation technology in stem cell therapy Hashemi M, Kalalinia F Life Sci 2015. 143:139-146
	Cell encapsulation: technical and clinical advances Orive G, Santos E, Poncelet D, Hernandez RM, Pedraz JL, Wahlberg LU, De Vos P, Emerich D Trends Pharmacol Sci 2015. 36(8):537-546
	Impact of donor age and weaning status on pancreatic exocrine and endocrine tissue maturation in pigs Krishnan R, Truong N, Gerges M, Stiewig M, Neel N, Ho-Nguyen K, Kummerfeld C, Alexander M, Spizzo T, Martin M, Foster CE 3rd, Monuki ES, Lakey JR Xenotransplantation 2015. 22(5):356-367
	Outpatient Management of Pediatric Type 1 Diabetes Beck JK, Cogen FR J Pediatr Pharmacol Ther 2015. 20(5):344-357
	Osteochondritis dissecans of the lateral femoral condyle in a patient affected by osteogenesis imperfecta: a case report Persiani P, Di Domenica M, Martini L, Ranaldi FM, Zambrano A, Celli M, Villani C J Pediatr Orthop B 2015. 24(6):521-525
	Immunogenicity of beta-cells for autologous transplantation in type 1 diabetes Schuetz C, Markmann JF Pharmacol Res 2015. 98:60-68
	Transplantable bioartificial pancreas devices: current status and future prospects Ludwig B, Ludwig S Langenbecks Arch Surg 2015. 400(5):531-540
	Overview of Cellular Transplantation in Diabetes Mellitus: Focus on the Metabolic Outcome Luzi L, Benedini S, Caumo A, Terruzzi I Adv Endocrinol 2015. 2015:967562